IHT Central Asia LLP is a Kazakh-Spanish joint venture and the only manufacturer of coronary stents and balloon catheters in Central Asia, established in 2023.
The company produces high-tech interventional cardiology devices based on European technology transfer. Production is localized in Astana and focused on treating ischemic heart disease and preventing myocardial infarction.
Product range:
Drug-eluting coronary stents (DEStiny)
Balloon catheters for angioplasty (Evolve)
Solutions for percutaneous coronary interventions
Key advantages:
Unique regional manufacturer
Proven European technology and clinical validation
Coverage of Kazakhstan demand (up to 36,000 stents/year)
Up to 30% lower cost than imports
Export to Central Asia and other markets
IHT Central Asia delivers advanced cardiovascular solutions focused on technology, accessibility, and reliability for healthcare systems.
What We Offer
Coronary drug-eluting stent DEStiny (Sirolimus)
Expanding export to Central Asia, the Caucasus, Southeast Asia, and the Gulf region
Evolve balloon catheter for PCI (percutaneous coronary interventions)
Cutting-edge European technology adapted for local healthcare systems
Unique Features
Certified quality: ISO 13485:2016
Full coverage of Kazakhstan’s annual PCI demand (36,000 stents/year)
Up to 30% lower price than the market average → saving public budgets
Proven technology: hundreds of thousands of successful cases worldwide
Contact Information
Nazarbayev University
Technopark, Astana, Kazakhstan
